Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.

This exploratory subgroup analysis of the MINDACT trial confirms the prognostic performance of the 70-gene signature in patients with high-risk features such as larger tumors, grade 3 tumors and 1-3 involved lymph nodes.

Robbert C. A. M. Gielen, C. Poncet, L. J. van 't Veer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.